Harry Hollema

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 623 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

Liesbeth Bergman, Maureen LR Beelen, M.P.W. Gallee et al. · The Lancet · 2000 · 550 citations

Medicine, Gynecology, Oncology +9

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 456 citations · Full text

Medicine, Gynecology, Oncology +17

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

Ninke Leffers, Marloes J.M. Gooden, Renske A. de Jong et al. · Cancer Immunology Immunotherapy · 2008 · 397 citations · Full text

Medicine, Oncology, Pathology +17

In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

Wouter B. Nagengast, Elisabeth G.E. de Vries, Geke A.P. Hospers et al. · Journal of Nuclear Medicine · 2007 · 314 citations · Full text

Medicine, Nuclear Medicine, Oncology +17